LIGAND PHARMACEUTICALS INC Total Revenue

• LIGAND PHARMACEUTICALS INC showed an increase of +60.4% in Total Revenue from 2024 to 2025.
• This data is from LIGAND PHARMACEUTICALS INC's annual report (Form 10-K), filed with the SEC on February 27, 2026.
• XBRL data for this metric is available from 2009 to 2025 (19 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q4 2013: $14.74 million | Q1 2014: $15.96 million | Q2 2014: $10.61 million | Q3 2014: $14.97 million | Q4 2014: $23.00 million | Q1 2015: $14.60 million | Q2 2015: $18.42 million | Q3 2015: $17.70 million | Q4 2015: $21.19 million | Q1 2016: $29.65 million | Q2 2016: $19.52 million | Q3 2016: $21.62 million | Q4 2016: $38.19 million | Q1 2017: $29.27 million | Q1 2017: $56.16 million | Q2 2017: $28.00 million | Q2 2017: $90.04 million | Q3 2017: $33.38 million | Q3 2017: $45.66 million | Q4 2017: $50.47 million | Q4 2017: $59.59 million | Q1 2018: $56.16 million | Q1 2018: $56.16 million | Q2 2018: $90.04 million | Q3 2018: $45.66 million | Q4 2018: $59.59 million | Q1 2019: $43.48 million | Q2 2019: $24.99 million | Q3 2019: $24.81 million | Q4 2019: $27.00 million | Q1 2020: $33.16 million | Q2 2020: $41.42 million | Q3 2020: $41.85 million | Q4 2020: $69.99 million | Q1 2021: $46.59 million | Q2 2021: $78.85 million | Q3 2021: $59.69 million | Q4 2021: $56.40 million | Q1 2022: $36.52 million | Q2 2022: $50.13 million | Q3 2022: $59.22 million | Q4 2022: $50.38 million | Q1 2023: $43.98 million | Q2 2023: $26.37 million | Q3 2023: $32.87 million | Q1 2024: $30.98 million | Q2 2024: $41.53 million | Q3 2024: $51.81 million | Q1 2025: $45.33 million | Q2 2025: $47.63 million | Q3 2025: $115.46 million.
• Over the full 19 years of available data (2009 to 2025), LIGAND PHARMACEUTICALS INC's Total Revenue has grown by 588.5%.
• Historical annual values: Fiscal year 2025: $268.09 million | Fiscal year 2024: $167.13 million | Fiscal year 2023: $131.31 million | Fiscal year 2022: $196.25 million | Fiscal year 2021: $241.54 million | Fiscal year 2020: $163.56 million | Fiscal year 2019: $120.28 million | Fiscal year 2018: $251.45 million | Fiscal year 2017: $141.10 million | Fiscal year 2017: $141.10 million | Fiscal year 2016: $108.97 million | Fiscal year 2016: $108.97 million | Fiscal year 2015: $71.91 million | Fiscal year 2014: $64.54 million | Fiscal year 2013: $48.97 million | Fiscal year 2012: $31.39 million | Fiscal year 2011: $30.04 million | Fiscal year 2010: $23.54 million | Fiscal year 2009: $38.94 million.
• Data sourced from SEC EDGAR public filings as of August 10, 2026.

Last verified: August 10, 2026